Chiara Mercinelli
@CMercinelli
Genito-Urinary Medical Oncologist at IRCCS San Raffaele Hospital - PhD Candidate in Molecular Medicine at Vita-Salute San Raffaele University
Proud to share that I’m officially part of the @EAU_YAUProstate working group of the @Uroweb It’s a great honour to be part of this international network ➡️ truly looking forward to growing through this experience!
Impact of molecular androgen and estrogen response scores on outcomes following neoadjuvant pembrolizumab in muscle-invasive #BladderCancer aacrjournals.org/clincancerres/… This post-hoc analysis of the PURE-01 trial investigated the influence of androgen and estrogen genomic signatures…
Video in @UroToday: @zklaassen_md interviews @AndreaNecchi about MRI radiomics analysis from the PURE-01 study: 3 cycles of neoadjuvant pembrolizumab in MIBC with pre- and post-treatment MRI imaging in 112 patients. Click to watch: urotoday.com/categories-med…
Just back from #UROonco25 in the stunning Seville! Honoured to be invited ➡️ a fantastic chance to dive into the latest in uro-oncology and catch up with friends and colleagues. @Uroweb @oncodaily @urofocus @SanRaffaeleMI
#UROonco25 starting today in the beautiful city of #Sevilla. Top experts from Europe and beyond come together to discuss about diagnosis and treatment of GU cancers. #ProstateCancer #KidneyCancer #BladderCancer Knowledge sharing and latest research with the common goal to…
The one and only @shilpaonc rocks the stage as usual with subgroup analyses of #EV302 Excellent and lively presentation with you at the Oral Abstract session! @ASCO #ASCO25
Is Artificial Intelligence applied to bladder MRI able to help predicting ypT response? Yes! Huge effort in collaboration with @MSKCancerCenter Radiology team #PURE01 #Bladdercancer @SanRaffaeleMI @MyUniSR @ASCO #ASCO25 @GiorgioBre @CMercinelli @vale_tateo @Anto_cigliola…
📢 #ASCO25 | SURE-02 Ph. II | Interim Results – SG + Pembro in CT-ineligible MIBC (n=40): cCR 38.7% (bladder preserved ~40%), ypT≤1 rate 51.6%; G≥3 AEs 12.9%. Luminal/GU tumors show highest ypT0; stromal signature linked to non-response. Insightful work by @AndreaNecchi et al.…
My mentor @AndreaNecchi delivered a brilliant presentation today at #ASCO2025 ➡️ 44% cCR in MIBC with SG+P combination in #SURE2 trial ➡️promising biomarker results that could guide future therapeutic choices ⭐️So proud to be part of this wonderful team @SanRaffaeleMI #GUoncology
Thanks @VJOncology for the interview today at #ASCO25 It was a pleasure to discuss #NUREcombo updated results & share insights on our work on #bladdercancer at @SanRaffaeleMI Grateful for the opportunity!
Many thanks to @CMercinelli for speaking with us at #ASCO25 today. 🌟The NURE-Combo study 🌟Patient selection for intensive multimodal approaches 🌟Managing immunotherapy toxicities Coming soon to VJOncology.com🎥 @ASCO #BlcSM #UroOnc
Happy to share the initial results of a machine learning tool applied to bladder MRI for the prediction of ypT0 or ypT<2 Response. AUC raises to 0.92 for ypT<2 in post Pembro features @MSKCancerCenter @SanRaffaeleMI @GiorgioBre @CMercinelli @vale_tateo @BrigidaMaiorano…
Ab#4518 @ASCO #ASCO25 by @AndreaNecchi 👉 bit.ly/43HuZI7👉Ph2 SURE-02 trial of neo-adj SG-pembro --> adj pembro in pts w/ MIBC #bladdercancer 👉clinical CR in ~39% of pts, allowing bladder preservation👇@F_Montorsi @CMercinelli @vale_tateo @OncoAlert @urotoday
The Top 10 Trials in GU Cancer for April 2025 are here, highlighted by @Larvol CLIN. #LARVOL #Oncology #GUCancer #GenitourinaryCancer #CancerResearch #ClinicalTrials #OncologyInsights | @DrChoueiri | @tompowles1 @DrYukselUrun | @montypal | @PGrivasMDPhD | @neerajaiims |…
Drs Shapiro and Karam with multicenter study on preop eval for sarc RCC @d_shapiro1 @ArighnoD @SpiessPhilippe @ccp1983 @spsutkaMD @urojdr @CMercinelli @AndreaNecchi @SurenaMatinMD @virajmaster
Bladder MRI radiomics & machine learning potential for path response prediction in #PURE01 will be disclosed #ASCO25 @ASCO from our joint @SanRaffaeleMI @MSKCancerCenter partnership #LarrySchwartz #AmitaDave @GiorgioBre @FDeCobelli @cigliola @CMercinelli @vale_tateo…
Get ready @ASCO - the @SanRaffaeleMI #GUoncology team is on its way! 💪🏼 @MyUniSR @ConquerCancerFd #ASCO25
Mixed abstract titles #ASCO25 from our rising stars @MyUniSR @SanRaffaeleMI - #PURE01 hits again with 5y FUP results presented by @vale_tateo - #NureCombo OS and bmks by @CMercinelli also #MeritAward recipient @ConquerCancerFd - #SURE01 interim EFS/OS results from neoadj SG in…
#SURE02 interim results will be disclosed at #ASCO25 #RapidOral session The trial provides SG-Pembro > bladder sparing for cCR > maintenance pembro to pts with MIBC Interim cCR survival and biomarker data will be presented @SanRaffaeleMI @MyUniSR @Veracyte @FoundationATCG…
Deeply honored to have been selected for the #ASCO2025 #MeritAward for our work on #NureCombo ➡️ Once again, many thanks to the @ConquerCancerFd and to my mentor, Prof. @AndreaNecchi for the incredible opportunity! @SanRaffaeleMI See you in Chicago!✨ @ASCO
Congratulations to the 2025 ASCO Annual Meeting Merit Award and Special Merit Award recipients. These awards will support 137 students and trainees who are first authors on abstracts selected for presentation at #ASCO25. View the full list of recipients: conquer.org/news/conquer-c…
Nice to have had the chance to meet and catch up with fantastic colleagues during #EAU25! Always great discussions and new ideas with Jeremy Teoh @Achard_Verane Chiara Mercinelli @BrigidaMaiorano Nello Cimino. Looking forward to future collaborations! #UroOncology #Networking
Just in @EUplatinum 👉Overview of T-cell engagers (TCEs) in #prostatecancer👉promising anti-tumor activity, but challenges remain👇Congrats @chadihc98 @ziremozay and the team @Huntsman_GU @EAntonarakis @AzadOncology bit.ly/3XJlg0x